Wim De Vlieger is a partner in the London office of Gibson, Dunn & Crutcher. Wim is co-chair of Private Equity in Europe and a member of the Mergers and Acquisitions and Capital Markets practice groups.

Wim advises private equity investors and their portfolio companies on a wide range of corporate transactions, including growth equity and control investments and co-investments, structured transactions, buy-out transactions, mergers and acquisitions, and exits. He also has considerable experience advising on strategic cross-border M&A transactions and on international capital market transactions. He has broad experience counselling clients across a wide range of European jurisdictions, with a focus on transactions in the technology and life sciences sectors.

Wim is recognised by The Legal 500 UK  2024 for Private Equity: Transactions – H igh-Value Deals, M&A: Upper Mid-Market and Premium Deals £750m+. He is also recognised by the 2024 edition of Best Lawyers in the United Kingdom  as a leading lawyer for Private Equity Law.

Wim received an LL.M. from the University of Pennsylvania Law School in 2007, a M.S. from HEC Paris in 2003 and a Masters of Law (cum laude) from the University of Leuven in 2002. He is admitted to practice in New York. He speaks Dutch and French.

Selected experience:*

• Arvelle Therapeutics, a Swiss-based biopharmaceutical company, on its sale to Angelini Pharma for a total cash consideration of up to US$960 million.
• Gilde Buy Out Partners in its investment in Caseking, a supplier of high-performance PC gaming equipment and peripherals.
• Goldman Sachs Private Capital, including on its:
  • investment and follow-on investment in Wolt, a delivery platform active in 18 countries;
  • investment in DocPlanner Group, an international healthcare booking platform provider; and
  • investment in technology platform LumApps.
• Kiniciti, a Welsh Carson, Anderson & Stowe platform, in its control investment in Ncardia, a company focused on developing stem cell-based solutions for drug discovery and cell therapy.
• KKR, including on its:
  • control investment in Biosynth Carbosynth, a life sciences reagents and custom synthesis and manufacturing services company headquartered in Switzerland;
  • investment in Leapwork, a Danish no-code automation platform;
  • investment and follow-on investment in Feedzai, a leading cloud-based financial risk management platform based in Portugal;
  • acquisition of Argenta, a leading animal pharmaceutical research and manufacturing company;
  • control investment in ReliaQuest, a cybersecurity technology company;
  • investment in Zwift, the at home training game connecting cyclists around the world;
  • investment and follow-on investment in music platform Artlist in Israel, and on Artlist’s acquisition of Motion Array in the U.S.;
  • exit from Paris-based company Ivalua; and
  • initial investment in, follow-on investment in and exit from KnowBe4, a security awareness training and simulated phishing platform provider.
• KKR and Goldman Sachs Private Capital on their respective investments in OutSystems, the global leader in low-code rapid application development, as part of a US$360 million investment round.
• NXP Semiconductors, on its merger with Freescale, on various issuances of senior cross-over notes and secured and unsecured high-yield notes, and on its initial public offering on NASDAQ and subsequent secondary offerings.

*Some of these representations occurred prior to Wim’s association with Gibson Dunn.